Montrusco Bolton Investments Inc. Trims Stake in IDEXX Laboratories, Inc. $IDXX

Montrusco Bolton Investments Inc. lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 23.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 176,932 shares of the company’s stock after selling 55,350 shares during the quarter. IDEXX Laboratories accounts for 1.5% of Montrusco Bolton Investments Inc.’s holdings, making the stock its 22nd largest holding. Montrusco Bolton Investments Inc.’s holdings in IDEXX Laboratories were worth $117,091,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. Blalock Williams LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at $590,000. Nordea Investment Management AB grew its stake in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after buying an additional 8,845 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after buying an additional 3,820 shares in the last quarter. Beacon Investment Advisory Services Inc. grew its stake in shares of IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after buying an additional 6,710 shares in the last quarter. Finally, Mediolanum International Funds Ltd grew its stake in shares of IDEXX Laboratories by 14.5% in the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after buying an additional 4,909 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Citigroup assumed coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $760.00.

Insiders Place Their Bets

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares of the company’s stock, valued at $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Up 0.9%

IDEXX Laboratories stock opened at $565.93 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $427.70 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a market capitalization of $44.95 billion, a P/E ratio of 43.30, a PEG ratio of 3.41 and a beta of 1.72. The stock has a 50-day simple moving average of $594.81 and a 200-day simple moving average of $652.81.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business earned $2.53 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.